Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02516696 · ClinicalTrials.gov registry record · Phase 3
BiRd vs. Rd as Initial Therapy in Multiple Myeloma
A Phase 3 study, sponsored by Weill Medical College of Cornell University.
- Terminated
- Registry status
- Phase 3
- Development phase
- 12
- Enrollment target
NCT02516696 is a Phase 3 study that was terminated before completion, run by Weill Medical College of Cornell University. The registered enrollment target is 12 participants.
The verdict
NCT02516696, a Phase 3 study, was terminated before completion, sponsored by Weill Medical College of Cornell University.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 12 participants
- Enrollment target
Study Summary
This is a randomized, open-label, phase III study to investigate the efficacy of combination therapy with an induction phase utilizing a combination clarithromycin (Biaxin®), lenalidomide (Revlimid®), dexamethasone (Decadron®), in multiple myeloma patients who are newly diagnosed and require treatment when compared to patients who receive lenalidomide and dexamethasone alone.
Interventions
- DRUG Dexamethasone
- DRUG Lenalidomide
- DRUG Clarithromycin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2016-02 |
| Est. Completion | 2022-07-22 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02516696
The ClinicalTrials.gov registry entry for NCT02516696 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Weill Medical College of Cornell University, which has 701 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Dexamethasone is the first listed.
NCT02516696 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02516696 about?
NCT02516696 is a clinical study titled "BiRd vs. Rd as Initial Therapy in Multiple Myeloma". This is a randomized, open-label, phase III study to investigate the efficacy of combination therapy with an induction phase utilizing a combination clarithromycin (Biaxin®), lenalidomide (Revlimid®), dexamethasone (Decadron®), in multiple myeloma patients who are newly diagnosed and require treatme...
What is the current status of trial NCT02516696?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 12 participants. The study started on 2016-02. Estimated completion is 2022-07-22.
What interventions are being tested in trial NCT02516696?
The interventions under investigation include: Dexamethasone (DRUG), Lenalidomide (DRUG), Clarithromycin (DRUG).
Who is sponsoring clinical trial NCT02516696?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.